RedPath Integrated Pathology, Inc. is the only commercial laboratory to offer the patented PathFinderTG® analysis for resolving indeterminate or equivocal cancer diagnoses.
RedPath is a CLIA-certified and CAP-accredited commercial laboratory that integrates molecular DNA analysis with the pathology review. We provide improved cancer diagnostic support for pathologists and clinicians when standard testing is inconclusive or there is a diagnostic dilemma.
PathFinderTG was developed over a 17-year period and is clinically validated as reported in over 100 peer-reviewed articles. More than 20,000 specimens have been analyzed using PathFinderTG technology.
Because cancer is a complex disease, it is not always possible to reach a definitive diagnosis. Advances in imaging have increased the observation of small abnormalities, which may or may not be of concern. In the absence of clear diagnostic information, patients may cycle through second opinions, testing, retesting, and delayed treatment—even undergoing unnecessary or inappropriate treatment. By examining molecular changes associated with an individual patient’s cancer, PathFinderTG provides physicians with an improved diagnosis, enabling them to define a better and more timely treatment plan.
The PathFinderTG analysis is easy to order and results are typically reported within seven business days. To order a PathFinderTG analysis, please contact Client Services at 1-800-495-9885.